326 related articles for article (PubMed ID: 37999111)
21. Targeted therapies for esophageal cancer.
Tew WP; Kelsen DP; Ilson DH
Oncologist; 2005 Sep; 10(8):590-601. PubMed ID: 16177283
[TBL] [Abstract][Full Text] [Related]
22. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
[TBL] [Abstract][Full Text] [Related]
23. Immune Checkpoint Inhibitors in Esophageal Carcinoma: Assessment of Efficacy Predictors of Response in Clinical Trials.
Abushukair H; Abushukair A; Singh M; Saeed A
Surg Oncol Clin N Am; 2024 Jul; 33(3):583-593. PubMed ID: 38789200
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials.
Huang ZH; Ma XW; Zhang J; Li X; Lai NL; Zhang SX
BMC Cancer; 2018 Nov; 18(1):1170. PubMed ID: 30477458
[TBL] [Abstract][Full Text] [Related]
25. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
Chan KK; Glenny AM; Weldon JC; Furness S; Worthington HV; Wakeford H
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010341. PubMed ID: 26625332
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in Gastric Cancer.
Högner A; Moehler M
Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan.
Harada K; Yamamoto S; Kato K
Expert Opin Biol Ther; 2022 Nov; 22(11):1333-1338. PubMed ID: 36266954
[TBL] [Abstract][Full Text] [Related]
28. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Advances in the Treatment of Gastroesophageal Cancers.
Li JJ; Rogers JE; Yamashita K; Waters RE; Blum Murphy M; Ajani JA
Biomolecules; 2023 May; 13(5):. PubMed ID: 37238666
[TBL] [Abstract][Full Text] [Related]
30. [History and Perspective of Chemotherapy in Advanced Esophageal Cancer].
Shiraishi K; Kato K
Gan To Kagaku Ryoho; 2024 Mar; 51(3):240-244. PubMed ID: 38494800
[TBL] [Abstract][Full Text] [Related]
31. Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma.
Kono K; Mimura K; Fujii H; Shabbir A; Yong WP; Jimmy So A
Ann Thorac Cardiovasc Surg; 2012; 18(6):506-13. PubMed ID: 23232268
[TBL] [Abstract][Full Text] [Related]
32. Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy.
Kakeji Y; Oshikiri T; Takiguchi G; Kanaji S; Matsuda T; Nakamura T; Suzuki S
Esophagus; 2021 Jan; 18(1):25-32. PubMed ID: 32964312
[TBL] [Abstract][Full Text] [Related]
33. Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice.
Nesline MK; Knight T; Colman S; Patel K
Clin Ther; 2020 Sep; 42(9):1682-1698.e7. PubMed ID: 32747004
[TBL] [Abstract][Full Text] [Related]
34. [A Case of Nivolumab Responding to Multiple Lymph Node Metastases during Multidisciplinary Treatment for Esophageal Cancer].
Yamamoto K; Hirao T; Oka Y; Takada N; Murao S; Higashiguchi M; Takeda T; Fujino S; Noguchi K; Danno K; Toyoda Y; Nakane S; Yamamoto H; Nakamichi I
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1995-1997. PubMed ID: 36733069
[TBL] [Abstract][Full Text] [Related]
35. Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial).
Goto H; Oshikiri T; Kato T; Nagatani Y; Funakoshi Y; Koterazawa Y; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Minami H; Kakeji Y
PLoS One; 2024; 19(4):e0299742. PubMed ID: 38635652
[TBL] [Abstract][Full Text] [Related]
36. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
Bhatia A; Burtness B
Drugs; 2023 Feb; 83(3):217-248. PubMed ID: 36645621
[TBL] [Abstract][Full Text] [Related]
37. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
[TBL] [Abstract][Full Text] [Related]
38. Esophageal cancer responsive to the combination of immune cell therapy and low-dose nivolumab: two case reports.
Takimoto R; Kamigaki T; Gotoda T; Takahashi T; Okada S; Ibe H; Oguma E; Goto S
J Med Case Rep; 2021 Apr; 15(1):191. PubMed ID: 33827668
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Szturz P; Vermorken JB
BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy.
Ma Y; Yu J; Ma X; Li Q; Su Q; Cao B
Asia Pac J Clin Oncol; 2024 Apr; 20(2):180-187. PubMed ID: 37171038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
